We are live on ! Find out more
BIOC

Biocept, Inc.

Delisted

BIOC was delisted on the 24th of October, 2023.

19 hedge funds and large institutions have $825K invested in Biocept, Inc. in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

181% more capital invested

Capital invested by funds: $294K → $825K (+$531K)

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

27% more funds holding

Funds holding: 1519 (+4)

Holders
19
Holders Change
+4
Holders Change %
+26.67%
% of All Funds
0.42%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
4
Reduced
Closed
4
Calls
Puts
Net Calls
Net Calls Change

BIOC Hedge Fund Activity: Q1 2020 in Review

19 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Biocept, Inc. (BIOC) for Q1 2020, worth a combined $825K — up 181% from $294K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new BIOC positions and 4 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $466K. The largest seller was Anson Funds Management, exiting entirely with an estimated $11K sold.

  • 19 institutional investors held Biocept, Inc. (BIOC) as of Q1 2020, up from 15 in Q4 2019.
  • Funds reported $825K of Biocept, Inc. stock for Q1 2020, up 181% quarter-over-quarter.
  • 8 funds opened new Biocept, Inc. positions in Q1 2020 and 4 closed out, a net change of +4 holders.
  • The largest Biocept, Inc. buyer in Q1 2020 was Renaissance Technologies, an estimated $466K added.
  • The largest Biocept, Inc. seller in Q1 2020 was Anson Funds Management, an estimated $11K sold.

Based on aggregated 13F filings for Q1 2020.